- Home
- BYAH vs CLRB Comparison
BYAH vs CLRB Comparison
Compare BYAH & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BYAH | CLRB |
|---|---|---|
| Founded | 2016 | 2002 |
| Country | China | United States |
| Employees | 41 | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8M | 12.9M |
| IPO Year | N/A | 2008 |
Fundamental Metrics
Financial Performance| Metric | BYAH | CLRB |
|---|---|---|
| Price | $1.16 | $3.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 451.7K | 46.4K |
| Earning Date | 01-01-0001 | 06-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.05 | $0.23 |
| 52 Week High | $2.77 | $10.19 |
Technical Indicators
Market Signals| Indicator | BYAH | CLRB |
|---|---|---|
| Relative Strength Index (RSI) | 52.36 | 55.10 |
| Support Level | $0.14 | $3.19 |
| Resistance Level | $2.77 | $3.60 |
| Average True Range (ATR) | 0.15 | 0.31 |
| MACD | -0.10 | 0.04 |
| Stochastic Oscillator | 5.29 | 68.47 |
Price Performance
Historical ComparisonAbout BYAH Park Ha Biological Technology Co. Ltd. Ordinary Shares
Park Ha Biological Technology Co Ltd is engaged in developing its private skincare label, direct skincare products sales and franchise alliances promotions. Its Park Ha brand focuses on providing solutions for problematic skin. The company's Operating Subsidiaries provide skincare and cosmetic products under its brand, Park Ha in China. Its Operating Subsidiaries develop its proprietary beauty products and offer complimentary after-sales beauty services in its physical stores.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.